BO-112

N/A

Report date: 2024/06/28 18:02:13
NME

Base Information

Drug NameBO-112
Drug Alias NameDouble stranded synthetic RNA formulated with the cationic carrier polyethyleneimine BO-112Nanoplexed Poly IC BO-112Nanoplexed Polyinosinic:Polycytidylic Acid BO-112BO-112
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionRetinoic acid-inducible gene I stimulantsToll like receptor 3 agonistsInterferon-induced helicase C domain-containing protein 1 agonists
TargetsRetinoic acid-inducible gene IToll like receptor 3Interferon-induced helicase C domain-containing protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHighlight Therapeutics SL
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of NavarraClinica Universidad De NavarraHighlight Therapeutics SL
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Basal CellMelanoma +[12] 
Inactive IndicationsStomach NeoplasmsColorectal NeoplasmsEsophageal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A